Real-World Treatment Patterns and Outcomes Among Patients with Early Non-Small Cell Lung Cancer.

ABSTRACT: Worldwide, about two million people are diagnosed with lung cancer each year, 85% of whom have non-small cell lung cancer (NSCLC). Recent progress in treating advanced/metastatic NSCLC with targeted therapies has shifted attention to early NSCLC (Stages I-IIIA) and perioperative (neoadjuvant and adjuvant) systemic therapies. However, our comprehension of how targeted therapeutics are incorporated into care and their impact on patient outcomes is just starting to unfold.

Methods

This retrospective observational study used a US nationwide electronic health record-derived deidentified database spanning January 2019-March 2024 and aimed to describe (1) eNSCLC patient demographic and clinical characteristics, (2) real-world neoadjuvant and adjuvant use, and (3) patient outcomes.

Resul

SUBMITTER: Deem JD 

PROVIDER: S-EPMC12026175 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature